|Videos|January 30, 2023
Relapse in Multiple Myeloma: Biochemical and Chemical
Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy
Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
5